Mats-Olof Wallin

Direttore Finanziario/CFO presso OxThera AB

73 anni

Health Technology

Consumer Services

Posizioni attive di Mats-Olof Wallin

Società	Posizione	Inizio	Fine
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Direttore Finanziario/CFO	01/01/2020	-

Società	Posizione	Inizio	Fine
KARO PHARMA AB (PUBL)	Direttore Finanziario/CFO	01/01/2018	01/10/2019
SWEDISH ORPHAN BIOVITRUM AB	Direttore Finanziario/CFO	08/04/2013	20/07/2018
BIOTAGE AB	Direttore Finanziario/CFO	17/05/2010	01/01/2012
BIOTAGE AB	Public Communications Contact	17/05/2010	01/01/2012

University of Uppsala

Undergraduate Degree

Distribuzione geografica

Svezia

Posizioni

Director of Finance/CFO	4
Public Communications Contact	1
Undergraduate Degree	1

Settori

Health Technology	5
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Aziende private

Health Technology